Market Overview

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Ampio Pharmaceuticals, Inc. – AMPE

Share:

Rosen Law Firm, a global investor rights law firm, announces it is
investigating potential securities claims on behalf of shareholders of
Ampio Pharmaceuticals, Inc. (NYSE:AMPE) resulting from allegations that
Ampio may have issued materially misleading business information to the
investing public.

On August 7, 2018, during aftermarket hours, Ampio filed a Form 8-K with
the SEC providing a regulatory update on the FDA's review of Ampion,
including the AP-003-A and AP-003-C trials. Ampio disclosed that it met
with the FDA in July 2018 and received a response letter thereto, which
stated that "as a single trial[,] the AP-003-A study alone does not
appear to provide sufficient evidence of effectiveness to support [the
Biologics License Application]." The FDA further provided that "the FDA
does not consider the AP-003-C trial to be an adequate and
well-controlled clinical trial." On this news, shares of Ampio's stock
fell sharply during intraday trading on August 8, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Ampio investors. If you purchased shares of Ampio please
visit the firm's website at http://www.rosenlegal.com/cases-1397.html
to join the class action. You may also contact Phillip Kim or Zachary
Halper of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com
or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm
or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class
Action Services for number of securities class action settlements in
2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View Comments and Join the Discussion!